Elevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study
Authors:
- Maren Poulsgaard JørgensenMJMaren Poulsgaard Jørgensen
- Andreas Kiesbye ØvlisenAØAndreas Kiesbye Øvlisen
- Jonas Faartoft JensenJonas Faartoft Jensen
- Helene Bjørg KristensenHKHelene Bjørg Kristensen
- Tarec Christoffer El‐GalalyTETarec Christoffer El‐Galaly
- Hanne VestergaardHVHanne Vestergaard
- Sigurd Broesby‐OlsenSBSigurd Broesby‐Olsen
- Marianne Tang SeverinsenMSMarianne Tang Severinsen
Open Access
- 15 November 2026
- journal article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (11)
Abstract
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.Keywords
Funding Information
- Aase og Ejnar Danielsens Fond
This publication has 48 references indexed in Scilit:
- Patients with eosinophilic oesophagitis in Denmark have higher use of psychotropic drugs: A Danish nationwide study of psychotropic drug use in 3367 patients and 16,835 matched comparatorsUnited European Gastroenterology Journal, 2024
- Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparatorsAmerican Journal of Hematology, 2022
- The Impact of Stigmatization of Psoriasis, Atopic Dermatitis and Mastocytosis in Different Areas of Life—A Qualitative Interview StudySkin Health and Disease, 2021
- Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patientsCancer Medicine, 2020
- Psychological functioning and quality of life in patients with mastocytosisAnnals of Allergy, Asthma & Immunology, 2020
- Positive predictive value of a register‐based algorithm using the Danish National Registries to identify suicidal eventsPharmacoepidemiology and Drug Safety, 2018
- Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centreEuropean Journal of Internal Medicine, 2016
- A Comprehensive Nationwide Study of the Incidence Rate and Lifetime Risk for Treated Mental DisordersJAMA Psychiatry, 2014
- The performance of different propensity score methods for estimating marginal hazard ratiosStatistics in Medicine, 2012
- Interpretation and Uses of Medical Statistics2000